Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Bacterial infections are common but have become increasingly resistant to drugs. The aim of the present study was to examine the combined treatment of traditional Chinese and Western medicine in 30 cases of pulmonary infection with multidrug resistant Acinetobacter baumannii. Patients were divided i...

Full description

Bibliographic Details
Main Authors:	PAN, TAO, LIU, XIAOYUN, XIANG, SHOUGUI, JI, WENLI
Format:	Online
Language:	English
Published:	D.A. Spandidos 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812438/

id	pubmed-4812438
recordtype	oai_dc
spelling	pubmed-48124382016-04-12 Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection PAN, TAO LIU, XIAOYUN XIANG, SHOUGUI JI, WENLI Articles Bacterial infections are common but have become increasingly resistant to drugs. The aim of the present study was to examine the combined treatment of traditional Chinese and Western medicine in 30 cases of pulmonary infection with multidrug resistant Acinetobacter baumannii. Patients were divided into groups A and B according to drug treatments. Cefoperazone or sulbactam and tanreqing were administered in group A, and cefoperazone or sulbactam in group B. The curative effect and prognosis of the two groups were recorded and the remaining treatments were performed routinely in the clinic. For the combined therapy group, which was administered sulperazone and tanreqing, 8 patients were recovered, 6 patients had significant effects, 3 patients exhibited some improvement and 1 patient had no response. One of the patients did not survive after 28 days. By contrast, there were 4 patients that were successfully treated, 3 patients with significant effects, 2 patients with some improvement and 2 patients had no response in the sulperazone group, and 4 patients did not survive after 28 days. In conclusion, the combined therapy of cefoperazone or sulbactam supplemented with tanreqing was identified to be more effective than cefoperazone or sulbactam as monotherapy, for treating multidrug resistant Acinetobacter baumannii. D.A. Spandidos 2016-04 2016-02-08 /pmc/articles/PMC4812438/ /pubmed/27073447 http://dx.doi.org/10.3892/etm.2016.3051 Text en Copyright: © Pan et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	PAN, TAO LIU, XIAOYUN XIANG, SHOUGUI JI, WENLI
spellingShingle	PAN, TAO LIU, XIAOYUN XIANG, SHOUGUI JI, WENLI Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection
author_facet	PAN, TAO LIU, XIAOYUN XIANG, SHOUGUI JI, WENLI
author_sort	PAN, TAO
title	Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection
title_short	Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection
title_full	Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection
title_fullStr	Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection
title_full_unstemmed	Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection
title_sort	treatment for patients with multidrug resistant acinetobacter baumannii pulmonary infection
description	Bacterial infections are common but have become increasingly resistant to drugs. The aim of the present study was to examine the combined treatment of traditional Chinese and Western medicine in 30 cases of pulmonary infection with multidrug resistant Acinetobacter baumannii. Patients were divided into groups A and B according to drug treatments. Cefoperazone or sulbactam and tanreqing were administered in group A, and cefoperazone or sulbactam in group B. The curative effect and prognosis of the two groups were recorded and the remaining treatments were performed routinely in the clinic. For the combined therapy group, which was administered sulperazone and tanreqing, 8 patients were recovered, 6 patients had significant effects, 3 patients exhibited some improvement and 1 patient had no response. One of the patients did not survive after 28 days. By contrast, there were 4 patients that were successfully treated, 3 patients with significant effects, 2 patients with some improvement and 2 patients had no response in the sulperazone group, and 4 patients did not survive after 28 days. In conclusion, the combined therapy of cefoperazone or sulbactam supplemented with tanreqing was identified to be more effective than cefoperazone or sulbactam as monotherapy, for treating multidrug resistant Acinetobacter baumannii.
publisher	D.A. Spandidos
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812438/
_version_	1613559414516613120

Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Similar Items